The Ipamorelin experiment ledger
This is a ledger of what studies administered, not a dose recommendation. The route and the question stay attached to every entry.
Healthy men, followed by bowel-surgery patients
The healthy-volunteer pharmacokinetic study tested 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg, administered by intravenous infusion over 15 minutes. There were 8 men at each dose level. The measurements concerned drug kinetics and the growth-hormone response.
The Phase 2 bowel-resection trial gave 0.03 mg/kg intravenously twice daily for up to 7 days. It tested recovery of eating, and missed its primary endpoint. These regimens describe the experiments that administered them.
I refuse to detach an amount from the experiment that gave it meaning. A figure from a short intravenous study cannot become a validated subcutaneous routine, a sleep treatment or an oral dose.
Female rat bones and cisplatin-treated ferrets
In the rat bone-growth experiment, adult female rats received 18, 90 or 450 micrograms daily, divided across three subcutaneous administrations for 15 days. The outcome was longitudinal bone growth.
The 2024 ferret experiment used 1–3 mg/kg intraperitoneally, into the abdominal cavity, in animals receiving cisplatin. The finding concerned reduced weight loss in those animals. Neither animal entry establishes a useful or safe human amount.
These differences in species, route and outcome are part of the numbers. Removing them produces a different claim.
A falling concentration, a brief hormone pulse
The human intravenous study found a terminal half-life of approximately 2 hours and a growth-hormone peak around 40 minutes. Half-life tracks the falling drug concentration. Duration of a health benefit would require an outcome study; hours of better sleep or recovery were not measured.
My concern with borrowing those timings for a routine is the missing middle: a measured pulse must first connect to a useful patient outcome. Oral ipamorelin adds a separate absorption question before even that connection can be tested.
CJC-1295 Ipamorelin: no established treatment amount
No human trial establishes a treatment amount for the pair. Online accounts of combined use are anecdotal accounts, not clinical evidence, and they do not provide a validated dose or schedule. Trials of either compound alone cannot choose an amount for both together.
The related search, how to reconstitute CJC-1295 ipamorelin 5mg, asks about turning powder into liquid. Reconstitution cannot establish the powder’s identity, sterility, safety or treatment benefit. This site supplies no preparation or administration instructions. The research file and safety entries explain why the gap cannot be filled by a mixing routine.